Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
ACQUIRED COMPANY
 
My Lists

TriVascular Technologies  (Stock symbol: TRIV ) Acquired by Endologix (2015 $ 211,000,000 )

3910 Brickway Blvd.
Santa Rosa, CA 95403
USA
707-543-8800
Website Company Summary Management Team
Management

CEO: Christopher Chavez (8/12/2012)
General Management: Joseph W Humphrey (2009) ; Shari L Allen (9/09)
Finance: Michael R Kramer (9/30/2010)
Technology: Michael V Chobotov (04/02/2008)
Sales/Marketing: Rob Woolley
Board

Former outside board: David J Kim (Pinnacle Ventures Partner)
Company

Business description: TriVascular develops devices that are used to treat abdominal aortic aneurysms. Conventional treatment involves surgery to graft metal stents to the aorta, allowing blood to bypass the aneurysm. The Trivascular device replaces much of the metal in a traditional stent with a liquid polymer injected into channels within the stent graft during the procedure, resulting in a graft that can use a small delivery system.
Capital

Rounds: 5
Recent Fundings: Nov 2013   Jun 2012
Capital raised: 255.0M
Last Round: 40.0M
Ownership: Acquired by Endologix (2015 $ 211,000,000 ) Ipo Filing
Stock Symbol: TRIV
VCs include: Delphi VenturesMPM CapitalBoston ScientificSaratoga VenturesPinnacle Ventures ;  New Enterprise Associates ;  Kearny Venture Partners;  Helix VenturesRedmile Group
Corporate investors: Kaiser Permanente Ventures

Last Tweets


 

Last Mentions


Overview
Record updated: Dec 2017
Sector: Medical
Year Founded: 2008
Headcount: 151-200 as of Nov 2009
Rounds: 5
Recent Fundings: Nov 2013   Jun 2012
Capital Raised: 255.0M
Last Round: 40.0M
Ownership: Acquired by Endologix (2015 $ 211,000,000 ) Ipo Filing
Stock Symbol: TRIV